Lixte Biotechnology Inc. (LIXT)
Lixte Biotechnology Statistics
Share Statistics
Lixte Biotechnology has 2.68M shares outstanding. The number of shares has increased by 19.33% in one year.
| Shares Outstanding | 2.68M |
| Shares Change (YoY) | 19.33% |
| Shares Change (QoQ) | 19.33% |
| Owned by Institutions (%) | 1.49% |
| Shares Floating | 1.87M |
| Failed to Deliver (FTD) Shares | 15 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 42.32K, so 1.58% of the outstanding shares have been sold short.
| Short Interest | 42.32K |
| Short % of Shares Out | 1.58% |
| Short % of Float | 2.27% |
| Short Ratio (days to cover) | 1.11 |
Valuation Ratios
The PE ratio is -1.27 and the forward PE ratio is null. Lixte Biotechnology's PEG ratio is 0.03.
| PE Ratio | -1.27 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 5.52 |
| P/FCF Ratio | -1.44 |
| PEG Ratio | 0.03 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Lixte Biotechnology.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.26, with a Debt / Equity ratio of 0.
| Current Ratio | 3.26 |
| Quick Ratio | 3.26 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 212.4 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.79M |
| Employee Count | 2 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -64.29% in the last 52 weeks. The beta is 0.32, so Lixte Biotechnology's price volatility has been higher than the market average.
| Beta | 0.32 |
| 52-Week Price Change | -64.29% |
| 50-Day Moving Average | 1.44 |
| 200-Day Moving Average | 1.89 |
| Relative Strength Index (RSI) | 44.82 |
| Average Volume (20 Days) | 66.03K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -3.57M |
| Net Income | -3.59M |
| EBITDA | -3.57M |
| EBIT | -3.6M |
| Earnings Per Share (EPS) | -1.59 |
Balance Sheet
The company has 1.04M in cash and 0 in debt, giving a net cash position of 1.04M.
| Cash & Cash Equivalents | 1.04M |
| Total Debt | 0 |
| Net Cash | 1.04M |
| Retained Earnings | -52.07M |
| Total Assets | 1.15M |
| Working Capital | 827.22K |
Cash Flow
In the last 12 months, operating cash flow was -3.16M and capital expenditures 0, giving a free cash flow of -3.16M.
| Operating Cash Flow | -3.16M |
| Capital Expenditures | 0 |
| Free Cash Flow | -3.16M |
| FCF Per Share | -1.41 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LIXT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for LIXT.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Jun 5, 2023. It was a backward split with a ratio of 1:10.
| Last Split Date | Jun 5, 2023 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -66.84 |
| Piotroski F-Score | 1 |